|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
P I3 K inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:2018
gptkb:FDA
|
|
gptkbp:brand
|
Copiktra
|
|
gptkbp:class
|
antineoplastic agent
|
|
gptkbp:clinical_trial
|
Phase 3
DUO trial
DYNAMO trial
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:developed_by
|
gptkb:Verastem,_Inc.
|
|
gptkbp:dosage_form
|
gptkb:tablet
|
|
gptkbp:duration
|
continuous until disease progression
|
|
gptkbp:formulation
|
film-coated tablet
|
|
gptkbp:has_ability
|
15 mg
25 mg
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Duvelisib
|
|
gptkbp:indication
|
relapsed or refractory disease
|
|
gptkbp:ingredients
|
C22 H23 N5 O3 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_monitored_by
|
liver function tests
complete blood count
|
|
gptkbp:is_used_for
|
gptkb:healthcare_organization
follicular lymphoma
|
|
gptkbp:launch_date
|
gptkb:2018
|
|
gptkbp:manager
|
oral
|
|
gptkbp:marketed_as
|
Copiktra
|
|
gptkbp:pharmacokinetics
|
inhibits cell proliferation
bioavailability 100%
|
|
gptkbp:population
|
adults
|
|
gptkbp:safety_features
|
risk of gastrointestinal perforation
risk of severe infections
monitor for signs of liver toxicity
|
|
gptkbp:shelf_life
|
24 months
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
increased risk of infections
hepatotoxicity
neutropenia
pneumonitis
colitis
|
|
gptkbp:social_structure
|
gptkb:drug
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:targets
|
P I3 K pathway
|
|
gptkbp:year_created
|
gptkb:2012
|
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
|
gptkbp:bfsLayer
|
5
|